Nordic Nanovector appoints Dr Sandra Jonsson as COO

Nordic Nanovector appoints Dr Sandra Jonsson as COO

OSLO, NORWAY: Nordic Nanovector ASA (OSE: NANOV) announced the appointment of Dr Sandra Jonsson, PhD, MBA as Chief Operating Officer.

Dr Sandra Jonsson will start on 10 January 2022 and takes over from Marco Renoldi, MD, who is retiring from the role but will remain as a consultant to the company.

Dr Sandra Jonsson is a results-driven international Life Science executive, with over 15 years of cross-functional experience in global pharmaceutical and biotechnology companies.

She has a proven track record of strategy & operations, portfolio management, leading on M&A integrations and executing corporate transformations as well as significant launch experience in the rare diseases and oncology areas.

Dr Jonsson joins Nordic Nanovector from Alexion Pharmaceuticals, at which she was Senior Director, Commercial International (prior to its acquisition by AstraZeneca in 2021) and before this, she was Head of Commercial Strategy & Operations in Region Europe at Shire (prior to its acquisition by Takeda in 2019). Previously Dr Jonsson spent 12 years at Novartis in a range of strategic and operational Global roles of increasing responsibility.

Erik Skullerud, CEO of Nordic Nanovector, said: “I am very pleased that Sandra has agreed to join us at what is a key time for Nordic Nanovector. Her broad strategic, commercial and project management experience, gained with both big pharma and leading biotech companies, will be critical as we execute on our plans to maximise the value of Betalutin® and our attractive pipeline of assets targeting CD37.

I would like to thank Marco Renoldi for his significant contribution to the company over the last seven years, in particular his work on our positioning and commercialisation plans for Betalutin.”

Sandra Jonsson, added: “I am excited to be joining the first-rate management team at Nordic Nanovector. Under Erik’s leadership the company has a clear strategy to capitalise on its radio immunotherapy expertise and the opportunities that can be addressed by its broader pipeline of drug candidates targeting CD37.

I believe that Betalutin, as a one-off treatment, has the potential to become an important therapy option for patients with follicular lymphoma, who fail earlier treatment options. I am looking forward to contributing to the company as it delivers a number of important value-enhancing milestones during 2022 and 2023.”

Dr Jonsson received an MBA from the University of St Gallen, Postdoc in Organic Chemistry and Chemical Biology from the ETH Zürich, PhD in Organic Chemistry from Stockholm University and an MS in Chemistry and Law from Uppsala University.

Add a Comment

Your email address will not be published. Required fields are marked *